News Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-15 pm EDT			5-day change	1st Jan Change
30.47 ^USD	+3.82%		-0.16%	-27.68%

Mar. 28	Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	MT
Mar. 13	Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	Mar. 28	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	Mar. 13	MT
Immunovant Awarded U.S. Patent for IMVT-1402	Mar. 12	AQ
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	Feb. 23	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	Feb. 20	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	Feb. 15	MT
Immunovant Posts Narrower Fiscal Q3 Loss	Feb. 12	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023	Feb. 12	AQ
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
North American Morning Briefing : Jobs Report Tops -2-	Feb. 02	DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	Jan. 29	MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	Jan. 09
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Dec. 21	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	Dec. 21	MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	Dec. 20	DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	Dec. 20	MT
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	Dec. 20	AQ
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	Dec. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunovant, Inc.

Equities

IMVT

US45258J1025

Summary

Filters